Varda to collaborate with United Therapeutics on microgravity drug research
AI-summarised brief · reviewed before publication
Varda Space Industries has signed a major agreement with United Therapeutics to develop improved drugs in microgravity. The collaboration aims to pioneer a new era in clinical development by studying novel formulations of drugs, starting with treatments for rare pulmonary disease, on Varda's spacecraft. Microgravity offers a unique environment to manufacture pharmaceuticals that are otherwise impossible on Earth, allowing for the creation of crystal structures that can lead to improved drug performance. The companies will use Varda's W-series spacecraft to conduct the drug studies, with results brought back on reentry capsules.
💡 Why It Matters
- · This collaboration has the potential to unlock billions of dollars in new markets for rare pulmonary disease treatments.
- · By leveraging the unique benefits of microgravity, United Therapeutics may be able to develop novel molecules that could revolutionize the treatment of this devastating disease.